Table 1. Antiproliferative activity of terpene-phospholipids against selected cell lines.
| Compounds | Acyl residue | Cell line /IC50 ±SD (μM) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| sn-1 | sn-2 | MV4-11 | A-549 | MCF-7 | LOVO | LOVO/DX | HepG2 | BALB/3T3 | ||
| 1a geranic acid | - | - | 310.77 ± 96.41 | n.a. | 447.09 ± 72.02 | 263.1 ± 32 | 492.3 ± 44.5 | n.a. | n.a. | |
| 1b citronellic acid | - | - | 254.49 ± 67.95 | n.a | 452.9 ± 96.0 | 249.3 ± 26.4 | 533.2 ± 36.7 | n.a. | n.a | |
| 3a | GA | GA | 96.66 ± 33.94* | 274.29 ± 9.42 | 236.33 ± 21.33* | 248.5 ± 9.3 | 278.8 ± 10.8* | 285.3 ± 5 | 273.16 ± 6.76 | |
| 3b | CA | CA | 130.08 ± 37.8^ | 203.1 ± 47.7 | 242.8 ± 45.1^ | 193.6 ± 22^ | 251.4 ± 23.4^ | 280.7 ± 1.8 | 283.7 ± 6.3 | |
| 7a | PA | GA | 60.89 ±10.86* | 72.1 ±14.4 | 104.66 ± 6.51* | 51.05±5.1* | 54.96±2.12* | 199.6±6.1 | 185.76 ± 15.2 | |
| 7b | PA | CA | 45.66 ± 7.63^ | 61.2 ± 6.0 | 155.0 ± 88.3^ | 53.9 ± 2.97^ | 57.1 ± 2.5^ | 103.4 ± 11.1 | 111.9 ± 29.3 | |
| 9a | GA | - | 323.5 ± 115.62 | n.a. | 522.96 ± 97.24 | 246.2 ± 9.9 | 526 ± 89.6 | n.a. | n.a. | |
| 9b | CA | - | 381.58 ± 24.49 | n.a | n.a | 286.7 ± 35.1 | 551.9 ± 18.5 | n.a. | n.a | |
| 10a | GA | PA | 38.21 ± 9.3* | 49.54 ± 1.88 | 52.45 ± 5.9* | 34.6 ± 1.6* | 51.9 ± 6.7* | 70.3 ± 8.6 | 65.8 ± 3.34 | |
| 10b | CA | PA | 57.06 ± 6.37^ | 60.2 ± 6.4 | 208.7 ± 25.7^ | 52.4 ± 3.6^ | 57 ± 1.8^ | 232.9 ± 14.7 | 92.9 ± 15.3 | |
| Cisplatin | - | - | 1.3 ± 0.47 | 8.6 ± 0.7 | 8.1 ± 0.03 | 2.56±0.35 | 3.17±0.2 | 2.38±0.64 | 4.2 ± 1.1 | |
| Doxorubicin | - | - | - | - | - | 0.117±0.012 | 6.53±0.93 | - | n.a. | |
n.a.—no activity in concentration of 5, 25, 125, 625 μM. IC50 –compound concentration leading to 50% inhibition of cell proliferation. Data are presented as mean ± SD of 3–5 independent experiments.
*—results within column which are significantly different in comparison to geranic acid, p < 0.05.
^—results within column which are significantly different in comparison to citronellic acid, p < 0.05.